News

Among patients with RA who achieved remission at month 6, between 79.1% and 84.9% were able to sustain remission at month 12.

A study presented at EULAR 2024 found a positive correlation between RA disease activity levels and mood disorders.

A greater proportion of patients in the FIL 200 mg group achieved meaningful patient-reported response compared with placebo.

Two patients with autoimmune diseases from 2 phase ½ RESET trials had complete B cell depletion within 15 days post-infusion with CABA-201 and needed no additional medication.

EULAR 2024 data link maternal intake of over 252 grams of fish per week with higher risk of juvenile idiopathic arthritis in offspring, but causation is unclear.

A study from EULAR details the ability of the FIRST self-questionnaire to identify fibromyalgia in patients with rheumatoid arthritis.

A recent study provides some evidence of the ability to potentially reduce belimumab dose in a subset of patients with SLE.

A study describes the structure and function differences of the Achilles tendon for PsA patients who self-report pain and those who don’t.

A recent study suggests fibromyalgia has little effect on polysomnographic indicators of obstructive sleep apnea-hypopnea syndrome.

A study examines why patients with inflammatory arthritis might seek emergency department care over ambulatory care.

At EULAR, Tonix Pharmaceuticals presented the phase 3 RESILIENT trial which met the primary endpoint of TNX-102 SL reducing daily pain intensity.

Patients with psoriasis on biological agents might have a lower PsA risk than those on methotrexate, but patients on topical therapy have an even lower risk, a study found.

Among patients with PsA, men tend to present more peripheral joint movement, and women tend to exhibit more axial involvement, a new study found.

These findings, presented at RAD 2024, highlight risk of atopic dermatitis patients for developing various cancers as well as major adverse cardiovascular events.

Some of the risk factors for RA-interstitial lung disease include male sex, older age, and smoking history, a study found.

An analysis of the REALISTIC trial from EULAR 2024 details the effects of certolizumab pegol in rheumatoid arthritis based on rheumatoid factor levels and prior TNF inhibitor use.

Findings highlight significant improvements in psychological constructs related to pain and quality of life following an 8-week intervention with hyperbaric oxygen therapy.

A new study found an indirect effect of RA on frailty index through inflammatory cytokines.

Findings highlight an urgent need for improved gout management strategies to reduce costs, improve quality of life, and reduce gout symptoms in patients with comorbid gout and CKD.

A propensity score matched analysis suggests use of SGLT2 inhibitors could reduce risk of negative outcomes in patients with systemic lupus erythematosus and type 2 diabetes.

Urate-lowering therapy was strongly associated with successful treat-to-target benchmarks in gout, including serum uric acid levels, but adherence remained low.

Exactly half of the sample had previously read or applied ≥ 1 Clinical Practice Guideline in the field of fibromyalgia.

Adults with active PsA treated with guselkumab exhibited durable achievement of study endpoints associated with disease control, irrespective of baseline characteristics.

An analysis of CDC WONDER data details disparities among the cardiovascular mortality rate for patients with rheumatoid arthritis in the US.

The approval was based on previous data from well-controlled RA studies coupled with findings from a multinational, dose-finding study of pediatric patients with pJIA.

Patients in the active counseling group were more likely to achieve low disease activity or remission.

Participants said the process was easy, convenient, and informed their self-management behaviors.

The rheumatology month in review addresses opioid concerns and promotes holistic care in managing chronic conditions.

cfPWV values were significantly higher in patients with PsA compared with controls, even after adjusting for confounders.

The approvals were based on data from well-controlled studies of the drug in adult patients with PsA and RA.